Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis

Autor Parise, Edison Roberto Autor UNIFESP Google Scholar
Oliveira, Ana Claudia de Autor UNIFESP Google Scholar
Conceição, Raquel D. O. Autor UNIFESP Google Scholar
Feldner, Ana Cristina de Castro Amaral Autor UNIFESP Google Scholar
Leite, Kátia Ramos Moreira Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Sírio-Libanês Hospital of São Paulo
Resumo The combined therapy with interferon alfa plus ribavirin (INF+RBV) is considered the most appropriate treatment for patients with chronic hepatitis C virus genotypes 2 and 3 in Brazil. However, wide variations in the rates of sustained viral response (SVR) have been reported among such patients. We evaluated, retrospectively, factors associated with SVR in subjects with chronic hepatitis C virus genotypes 2 and 3 and that received medication from the Health Secretariat of the state of São Paulo. One-hundred-seventy-seven consecutive patients with chronic hepatitis C were treated for 24 or 48 weeks according to the viral genotype. Patients co-infected with associated hepatic diseases or who had problems with alcohol abuse were excluded. The genotype of the HCV-RNA was identified through restriction analysis, the viral load through quantitative PCR (Amplicor, Roche) and the degree of hepatic fibrosis according to the Metavir score. Demographic, virological and histological parameters were submitted to binary logistic regression analysis to identify the variables associated with SVR. The overall rate of SVR was 36.4% for the 177 patients, and genotype 2 or 3 was the main parameter independently associated with SVR. Among the 77 patients with these viral genotypes, only the stage of fibrosis had a significant effect on the SVR (odds ratio (OR) = 3.035; 95% CI (confidence interval) = 1.196-7.699; p=0.019). The rate of SVR among the subjects with fibrosis at an advanced stage (F3-F4) was 38%, compared to 75% for patients with fibrosis at an initial stage (F0-F2). Consequently, other therapeutic options should be considered for patients with genotypes 2 and 3 who have advanced fibrosis.
Palavra-chave Interferon alpha
ribavirin
treatment of chronic C hepatitis
genotype 2 and 3
hepatic fibrosis
Idioma Inglês
Data de publicação 2006-04-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 10, n. 2, p. 78-81, 2006.
ISSN 1413-8670 (Sherpa/Romeo)
Publicador Brazilian Society of Infectious Diseases
Extensão 78-81
Fonte http://dx.doi.org/10.1590/S1413-86702006000200002
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1413-86702006000200002 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/3024

Exibir registro completo




Arquivo

Nome: S1413-86702006000200002.pdf
Tamanho: 49.67KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta